We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth
Read MoreHide Full Article
On Dec 27, we issued an updated research report on Zimmer Biomet Holdings Inc. (ZBH - Free Report) . While strategic acquisitions and planned operational execution buoy optimism on the stock, issues like macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations adversely affected the company’s sales. The company carries a Zacks Rank #3 (Hold).
In order to address several near-term challenges, management recently started to review its 2018 operating plan to clearly define its go-forward strategies in a number of key areas. In this regard, the company has identified several immediate opportunities to improve Zimmer Biomet’s operational execution.
First, the company has plans to continue with its efforts in completing its quality remediation work at the Warsaw North Campus. In this context, to support the quality compliance of its manufacturing network, Zimmer Biomet will consistently invest in developing a best-in-class quality management system.
Second, in order to revive accelerated sales recapture, the company aims to steadily focus on fully restoring the supply of certain key brands within knee, hip and SET categories.
Third, with respect to commercial strategy, Zimmer Biomet’s immediate priorities are to restore supply, engage with the sales channel and return to offense. In addition to sales recapture, the company will keep a close watch on the significant quantity of commercial releases scheduled in 2018. Per the latest update, Zimmer Biomet is on track to build a complete product portfolio in the back half of 2019.
Also, the company is progressing well with its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application. Moreover, management has notified that Zimmer Biomet is ahead of its schedule to perform its first case in Australia.
This apart, improvement in the company’s global Knee and Hip sales performance and growth in the Asia Pacific region are encouraging. Banking on its priority goals like quality remediation, supply recovery efforts and product launches, Zimmer Biomet is constantly reporting solid top-line figures within its S.E.T arm.
On the flip side, we are concerned about the escalating costs and expenses weighing on the company’s bottom line. Also, declining dental sales at CER is a drag. Negative currency movements persist to be a major headwind for the company.
Over the past three months, shares of this leading musculoskeletal healthcare company have underperformed the industry. The stock has lost 4.5%, comparing unfavorably with the industry’s 4.4% fall.
Key Picks
Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Surmodics, Inc. (SRDX - Free Report) and Veeva Systems (VEEV - Free Report) .
Integer Holdings has an earnings growth rate of 31.2% for the first quarter of 2019. The stock has a Zacks Rank #2 (Buy).
Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank of 2 currently.
Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth
On Dec 27, we issued an updated research report on Zimmer Biomet Holdings Inc. (ZBH - Free Report) . While strategic acquisitions and planned operational execution buoy optimism on the stock, issues like macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations adversely affected the company’s sales. The company carries a Zacks Rank #3 (Hold).
In order to address several near-term challenges, management recently started to review its 2018 operating plan to clearly define its go-forward strategies in a number of key areas. In this regard, the company has identified several immediate opportunities to improve Zimmer Biomet’s operational execution.
First, the company has plans to continue with its efforts in completing its quality remediation work at the Warsaw North Campus. In this context, to support the quality compliance of its manufacturing network, Zimmer Biomet will consistently invest in developing a best-in-class quality management system.
Second, in order to revive accelerated sales recapture, the company aims to steadily focus on fully restoring the supply of certain key brands within knee, hip and SET categories.
Third, with respect to commercial strategy, Zimmer Biomet’s immediate priorities are to restore supply, engage with the sales channel and return to offense. In addition to sales recapture, the company will keep a close watch on the significant quantity of commercial releases scheduled in 2018. Per the latest update, Zimmer Biomet is on track to build a complete product portfolio in the back half of 2019.
Zimmer Biomet Holdings, Inc. Price
Zimmer Biomet Holdings, Inc. Price | Zimmer Biomet Holdings, Inc. Quote
Also, the company is progressing well with its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application. Moreover, management has notified that Zimmer Biomet is ahead of its schedule to perform its first case in Australia.
This apart, improvement in the company’s global Knee and Hip sales performance and growth in the Asia Pacific region are encouraging. Banking on its priority goals like quality remediation, supply recovery efforts and product launches, Zimmer Biomet is constantly reporting solid top-line figures within its S.E.T arm.
On the flip side, we are concerned about the escalating costs and expenses weighing on the company’s bottom line. Also, declining dental sales at CER is a drag. Negative currency movements persist to be a major headwind for the company.
Over the past three months, shares of this leading musculoskeletal healthcare company have underperformed the industry. The stock has lost 4.5%, comparing unfavorably with the industry’s 4.4% fall.
Key Picks
Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) , Surmodics, Inc. (SRDX - Free Report) and Veeva Systems (VEEV - Free Report) .
Integer Holdings has an earnings growth rate of 31.2% for the first quarter of 2019. The stock has a Zacks Rank #2 (Buy).
Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank of 2 currently.
Veeva Systems’ long-term earnings growth rate is estimated at 19.5%. The stock flaunts a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>